OncoPanCure Launches Its Family, Friends & Fools Investment Round

OncoPanCure Therapeutics has officially launched its Family, Friends & Fools (FFF) investment round to support the next stage of preclinical development of OPC080, its innovative drug candidate for pancreatic cancer.

Founded in July 2026 as a biotechnology spin-off emerging from research at IQS School of Engineering and Xenopat, OncoPanCure is developing OPC080, a novel small-molecule therapeutic candidate designed to disrupt cancer cell survival signaling through multitarget MAPK modulation.

Following encouraging preclinical results, including antitumor activity in pancreatic cancer models and promising combination studies, the company is preparing the next steps towards IND-enabling development and regulatory readiness.

The FFF investment round aims to raise between €500,000 and €1 million to support additional preclinical studies, further characterize the therapeutic potential of OPC080, and advance the preparations for regulatory development.

Investor Presentation – November 18, 2026

To introduce the company, present the scientific progress achieved so far and explain its development and financing strategy, OncoPanCure will host an investor presentation:

Date: Wednesday, November 18, 2026
Time: 19:00 CET
Venue: IQS School of Engineering, Via Augusta 390, Barcelona, Spain
Format: In person and online

The presentation will cover the scientific foundations of OPC080, its preclinical development, the company’s roadmap, the team, and the structure of the FFF investment round.

Registration is required for both in-person and online attendance.

REGISTER FOR THE INVESTOR PRESENTATION → https://forms.gle/HNU683EU1Q7Za2728

For additional information, please contact info@oncopancure.com.

About OncoPanCure Therapeutics

OncoPanCure Therapeutics is a biotechnology company developing first-in-class small-molecule therapies for pancreatic cancer. The company was founded in 2026 as a spin-off from IQS School of Engineering (Universitat Ramon Llull) and Xenopat S.L. to advance OPC080, a novel therapeutic candidate currently in preclinical development.